Fennec Pharmaceuticals Inc.

As of June 30, 2026, Fennec Pharmaceuticals Inc. carries a market capitalization of 327.57M, placing it among publicly traded companies globally. Its enterprise value stands at 291.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fennec Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Fennec Pharmaceuticals Inc. has 35.03M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.77, and the price-to-book ratio stands at 8.82.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 291.46M versus a market cap of 327.57M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fennec Pharmaceuticals Inc. maintains a current ratio of 5.85, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -5.39, reflecting losses generated across the asset base. The company generates approximately 1.51M in revenue per employee across its workforce of 34.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.62 indicates how many times Fennec Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Fennec Pharmaceuticals Inc. recorded 36,762.60 in income tax expense. The company reported a pretax loss of -2.72M and -2.85M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Fennec Pharmaceuticals Inc.'s stock has gained approximately 22.15% over the past 52 weeks. The 50-day moving average sits at 9.67, while the 200-day moving average is 7.94.

Over the twelve months ended June 30, 2026, Fennec Pharmaceuticals Inc. generated 51.84M in revenue and converted that into -2.85M in net income, yielding earnings per share of -0.09. EBITDA reached -894,556.60, while operating income came in at -1.02M.

These figures are as of June 30, 2026. Total book value stands at 37.15M, with working capital of 52.61M providing operational flexibility.

Fennec Pharmaceuticals Inc. produced -1.79M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Fennec Pharmaceuticals Inc. posted a gross margin of 93.73, reflecting its pricing power and cost economics. The operating margin of -1.96 and net profit margin of -5.49 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.57, meaning Fennec Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Fennec Pharmaceuticals Inc.'s most recent stock split took place on September 5, 2014 with a 3:1 split ratio.

As of June 30, 2026, Fennec Pharmaceuticals Inc. has an Altman Z-Score of 4.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.